New Research Suggests Shingles Vaccine Might Help Slow Dementia Progression
A recent study from Stanford University has provided intriguing evidence that the shingles vaccine may play a role in slowing the progression of dementia. Previous research indicated that older individuals who received the shingles vaccine were 20% less likely to develop dementia within seven years compared to those who did not get vaccinated.
Dr. Pascal Geldsetzer, an assistant professor of medicine and the study’s senior author, stated, “For the first time, we have evidence that suggests a likely cause-and-effect link between getting the shingles vaccine and preventing as well as treating dementia.”
The study focused on public health data from Wales, where eligibility for the shingles vaccine, known as Zostavax, was determined by birth date. This setup created two nearly identical groups of older adults, differentiated only by whether or not they had received the vaccine, allowing researchers to analyze dementia rates while minimizing biases common in observational studies.
Following further analysis of the records, researchers found that the benefits of the vaccine extended not only to those at the earliest signs of cognitive decline but also to individuals in advanced stages of dementia. Over nine years, vaccinated individuals had lower rates of mild cognitive impairment. Additionally, those who received the vaccine post-diagnosis showed a significant reduction in dementia-related death rates over the next nine years. In fact, nearly half of the Welsh seniors with dementia at the start of the vaccination program passed away from the illness, compared to just 30% of those who had been vaccinated.
Geldsetzer noted that research has suggested a connection between viruses targeting the nervous system and the development of dementia. The chickenpox virus, which can reactivate in older age to cause shingles, has been linked to inflammation in the brain—an issue thought to raise dementia risk. By preventing these viral flare-ups, the vaccine might help reduce inflammation and, in turn, the risk of developing dementia.
Despite these promising findings, the study does have limitations. As Geldsetzer explained, there is a notable difference in health behaviors between those who choose to get vaccinated and those who don’t, and the available health records do not provide complete information regarding patients’ dietary habits or physical activity levels.
If confirmed by further randomized trials, these results could mark a significant breakthrough in dementia research and clinical medicine. Researchers are eager to explore the implications of these findings on public health and future studies related to dementia’s causes.
In the meantime, experts are hopeful about the shingles vaccine’s potential benefits for older adults in relation to cognitive health.
